Clinical Trial Search

Primary: Visual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose) — 46.21; 45.48; 20.21; 19.94 units on a scale

Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…

Primary: Probability of Dose-Limiting Toxicity (DLT) — 0; 12.5; 12.5; 50 percent probability

Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049

Primary: Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Visual Analogue Score (VAS) at Week 8 — 53.05; 55.89; 31.62; 30.51 score on a scale — p=0.2678

Primary: Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib — 8 percentage of participants

Primary: Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP) — 2.00 scores on a scale

Primary: Safety: Change in DAS28-CRP Score From Baseline to Week 24 in Patients Treated With GP2015 and Patients Treated With Enbrel — -2.80; -2.73 scores on a scale

Primary: Breast Cell Proliferation Levels Between the Two Oral Contraceptive Dose Groups — 7.5; 12.4 Percent of cells staining for Ki67

Primary: Kaplan-Meier Analysis of Percentage of Participants With Clinically Significant Infection by Visit — 4.69; 8.33; 3.70; 7.81 Percentage of Participants — p=0.6694

Primary: Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug. — 2.455; 2.131…

Primary: Oocytes — 19; 47 oocytes

Primary: Change in Postprandial Glucose Levels After Mixed Meal Test — 7.10; 6.52; 6.44; 6.39 mmol/L — p=0.028

Primary: Sputum White Cell Count — 6.93; 6.81 log 10 (cells/mL) — p=0.2772

Primary: TT Cases Screened Positive by CTA's and Confirmed by Graders — 9; 50 Participants